See more : Suprajit Engineering Limited (SUPRAJIT.NS) Income Statement Analysis – Financial Results
Complete financial analysis of Timber Pharmaceuticals, Inc. (TMBR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Timber Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- United Overseas Bank Limited (UOVEY) Income Statement Analysis – Financial Results
- KBS Real Estate Investment Trust III, Inc. (KBSR) Income Statement Analysis – Financial Results
- Rockcliff Metals Corporation (RCLF.CN) Income Statement Analysis – Financial Results
- Xero Limited (XRO.AX) Income Statement Analysis – Financial Results
- Pixium Vision SA (PXMVF) Income Statement Analysis – Financial Results
Timber Pharmaceuticals, Inc. (TMBR)
About Timber Pharmaceuticals, Inc.
Timber Pharmaceuticals LLC, a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for orphan dermatologic diseases. The company's lead product candidates include TMB-001, a patented topical formulation of isotretinoin that has completed Phase 2b clinical trial for the treatment of moderate to severe subtypes of CI, a group of rare genetic keratinization disorders; and TMB-002, a proprietary topical formulation of rapamycin, which is in Phase 2b clinical trial for the treatment of facial angiofibroma in tuberous sclerosis complex, a multisystem genetic disorder resulting in the growth of hamartomas in multiple organs. It is also involved in the development of TMB-003, a proprietary formulation of Sitaxsentan, which is a selective endothelin-A receptor antagonist that is in preclinical development for the treatment of sclerotic skin diseases. In addition, the company engages in the development of BPX-01, which is in Phase 3 topical minocycline for the treatment of inflammatory lesions of acne vulgaris; and BPX-04 that is a Phase 3 ready topical minocycline for the treatment of papulopustular rosacea. It has license agreement with AFT Pharmaceuticals Limited. The company was founded in 2019 and is headquartered in Basking Ridge, New Jersey.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 83.18K | 295.74K | 453.81K | 324.65K | 57.00K | 73.00K | 100.00K | 64.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 13.30M | 6.15M | 1.50M | 3.38M | 83.00K | 250.00K | 516.00K | 237.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -13.22M | -5.85M | -1.05M | -3.06M | -26.00K | -177.00K | -416.00K | -173.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | -15,892.35% | -1,979.40% | -230.78% | -941.95% | -45.61% | -242.47% | -416.00% | -270.31% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 13.30M | 6.15M | 15.10M | 3.38M | 9.08M | 9.14M | 10.16M | 5.70M | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 5.24M | 5.14M | 4.65M | 4.17M | 0.00 | 52.31K | 27.96K | 59.11K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 2.16M | 2.42M | 3.20M | 5.11M | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 6.02M | 5.39M | 4.06M | 586.56K | 7.40M | 7.56M | 7.85M | 9.28M | 0.00 | 52.31K | 27.96K | 59.11K |
| Other Expenses | -83.18K | -590.79K | -453.81K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 19.24M | 10.95M | 18.71M | 586.72K | 16.48M | 16.70M | 18.01M | 14.99M | 0.00 | 52.31K | 27.96K | 59.11K |
| Cost & Expenses | 19.24M | 10.95M | 18.71M | 3.97M | 16.56M | 16.95M | 18.53M | 15.22M | 0.00 | 52.31K | 27.96K | 59.11K |
| Interest Income | 2.45K | 15.55K | 816.66K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.00 | 2.00 | 0.00 |
| Interest Expense | 228.46K | 15.55K | 4.42M | 0.00 | 28.00K | 364.00K | 163.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 77.45K | 272.88K | 2.43M | 171.86K | 62.00K | 52.00K | 260.00K | 86.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -19.16M | -10.38M | -17.78M | -45.56K | -17.17M | -16.88M | -17.98M | -15.16M | 0.00 | -52.31K | -27.96K | -59.11K |
| EBITDA Ratio | -23,032.75% | -3,601.23% | -3,917.31% | -14.03% | -30,115.79% | -32,717.81% | -17,981.00% | -24,231.25% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -19.24M | -10.65M | -20.21M | -3.64M | -17.23M | -23.94M | -18.24M | -15.59M | 0.00 | -52.31K | -27.96K | -59.11K |
| Operating Income Ratio | -23,125.86% | -3,601.23% | -4,453.82% | -1,122.63% | -30,224.56% | -32,789.04% | -18,241.00% | -24,365.63% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -136.45K | -19.17K | 5.13M | -156.00 | -750.00K | 238.00K | -163.00K | -436.00K | 0.00 | 1.00 | 2.00 | 0.00 |
| Income Before Tax | -19.37M | -10.67M | -15.08M | -3.64M | -17.26M | -16.64M | -18.40M | -15.59M | 0.00 | -52.30K | -27.96K | -59.11K |
| Income Before Tax Ratio | -23,289.91% | -3,607.72% | -3,322.93% | -1,122.68% | -30,273.68% | -22,791.78% | -18,404.00% | -24,365.63% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 7.60K | -30.24K | 37.84K | -156.00 | 2.00K | -7.66M | 2.00K | 4.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -19.38M | -10.64M | -15.12M | -3.69M | -17.26M | -8.98M | -18.41M | -15.60M | 0.00 | -52.30K | -27.96K | -59.11K |
| Net Income Ratio | -23,299.05% | -3,597.49% | -3,331.27% | -1,136.66% | -30,277.19% | -12,298.63% | -18,406.00% | -24,371.88% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -9.19 | -13.15 | -48.15 | -29.31 | -1.34K | -1.57K | -7.71K | -13.03K | 0.00 | -0.01 | 0.00 | -0.01 |
| EPS Diluted | -9.19 | -13.15 | -48.15 | -29.31 | -1.34K | -1.57K | -7.71K | -13.03K | 0.00 | -0.01 | 0.00 | -0.01 |
| Weighted Avg Shares Out | 2.11M | 808.81K | 314.00K | 125.91K | 12.88K | 5.73K | 2.39K | 1.20K | 204.34K | 9.00M | 9.00M | 8.21M |
| Weighted Avg Shares Out (Dil) | 2.11M | 808.81K | 314.00K | 125.91K | 12.88K | 5.73K | 2.39K | 1.20K | 204.34K | 9.00M | 9.00M | 8.21M |
Why Is Timber Pharmaceuticals (TMBR) Stock Up 96% Today?
LEO Pharma Signs Agreement to Acquire Timber Pharmaceuticals
Timber Pharmaceuticals to be Acquired by LEO Pharma
Timber Pharmaceuticals Discloses Communication From NYSE American
Timber (TMBR) Surges on Carcinogenicity Waiver for TMB-001
Bears are Losing Control Over Timber Pharmaceuticals, Inc. (TMBR), Here's Why It's a 'Buy' Now
Building a Penny Stocks Portfolio For Long Term
Penny Stock Investing: How to Analyze Market Conditions
Why Is Timber Pharmaceuticals (TMBR) Stock Up 61% Today?
Top Penny Stocks To Buy? 4 For Your Watch List Before Next Week
Source: https://incomestatements.info
Category: Stock Reports